Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in Interest ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

SAB Biotherapeutics (SABS) Change in Interest Receivables (2024 - 2025)

SAB Biotherapeutics (SABS) has disclosed Change in Interest Receivables for 2 consecutive years, with $386827.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Change in Interest Receivables rose 1019.0% year-over-year to $386827.0, compared with a TTM value of $891826.0 through Dec 2025, up 1522.83%, and an annual FY2025 reading of $891826.0, up 1522.83% over the prior year.
  • Change in Interest Receivables was $386827.0 for Q4 2025 at SAB Biotherapeutics, down from $559954.0 in the prior quarter.
  • Across five years, Change in Interest Receivables topped out at $559954.0 in Q3 2025 and bottomed at -$127877.0 in Q3 2024.